The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A thermoresponsive hydrogel system for long-acting corticosteroid delivery into the paranasal sinuses
Abstract
Delivering localized treatment to the paranasal sinuses for diseases such as chronic rhinosinusitis (CRS) is particularly challenging because of the small natural openings leading from the sinuses that can be further obstructed by presence of inflammation. As such, oral steroids, topical nasal sprays or irrigation, and surgery can be utilized to treat persistent sinonasal inflammation, but there exists a need for post-operative options for long-term steroid delivery to prevent disease recurrence. In the present study, a Thermogel, Extended-release Microsphere-based-delivery to the Paranasal Sinuses (TEMPS) is developed with the corticosteroid mometasone furoate. Specifically, the bioactive steroid is released for 4 weeks from poly(lactic-co-glycolic acid) (PLGA) microspheres embedded in a poly(N-isopropylacrylamide) (p-NIPAAm)-based hydrogel. The temperature-responsive system undergoes a reversible sol-gel transition at 34–35 °C such that it can be applied as a liquid at ambient temperature, conforming to the sinonasal epithelium as it gels. In a rabbit model of CRS, TEMPS was maintained in rabbit sinuses and effectively reduced sinonasal inflammation as characterized by micro-computed tomography and histopathology analysis. Ultimately, the combination of controlled release microspheres with a thermoresponsive hydrogel provides flexibility for encapsulating therapeutics in a reversible and conforming system for localized delivery to the sinuses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These systems have already demonstrated their potential in preclinical models of CRS, successfully delivering corticosteroids and sustaining a reduction in inflammation for up to 4 weeks [40].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Consensus Statement on Allergy and Rhinology: Rhinosinusitis
Orlandi, R. R., Kingdom, T. T., Hwang, P. H., Smith, T. L., Alt, J. A., Baroody, F. M., Batra, P. S., Bernal‐Sprekelsen, M., Bhattacharyya, N., Chandra, R. K., et al. (2016) · International Forum of Allergy & Rhinology · doi:10.1002/alr.21695 · Cited by 892
Alexander, A., Ajazuddin, Khan, J., Saraf, S., & Saraf, S. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.07.005 · Cited by 249
Research works printed but not linked: 44
- DeConde, 2016, Chronic rhinosinusitis: epidemiology and burden of disease, Am. J. Rhinol. Allergy, 30, 134, 10.2500/ajra.2016.30.4297 · DOI · Paper page
- Rosenfeld, 2015, Clinical practice guideline (update): adult sinusitis, Otolaryngol. - Head Neck Surg. (United States), 152, S1
- Soler, 2011, Health state utility values in patients undergoing endoscopic sinus surgery, Laryngoscope, 121, 2672, 10.1002/lary.21847 · DOI · Paper page
- Piromchai, 2013, Chronic rhinosinusitis and emerging treatment options, Int. J. Gen. Med., 6, 453, 10.2147/IJGM.S29977 · DOI
- Möller, 2013, Topical drug delivery in chronic rhinosinusitis patients before and after sinus surgery using pulsating aerosols, PLoS One, 8, 10.1371/journal.pone.0074991 · DOI
- Snidvongs, 2017, Update on intranasal medications in rhinosinusitis, Curr Allergy Asthma Rep, 17, 10.1007/s11882-017-0720-3 · DOI
- Li, 2009, Controlled steroid delivery via bioabsorbable stent: safety and performance in a rabbit model, Am. J. Rhinol. Allergy., 23, 591, 10.2500/ajra.2009.23.3391 · DOI
- Marple, 2012, Advance II: a prospective, randomized study assessing safety and efficacy of bioabsorbable steroid-releasing sinus implants, Otolaryngol. Neck Surg., 146, 1004, 10.1177/0194599811435968 · DOI
- Lavigne, 2014, Steroid-eluting sinus implant for in-office treatment of recurrent nasal polyposis: a prospective, multicenter study, Int. Forum Allergy Rhinol., 4, 381, 10.1002/alr.21309 · DOI
- Tang, 2019, Multiple bioabsorbable corticosteroid-eluting stent placement with associated skull base injury, Laryngoscope, 129, 1494, 10.1002/lary.27659 · doi:10.1002/lary.27659
- Fedorchak, 2017, Long term glaucoma drug delivery using a topically retained gel/microsphere eye drop, Sci. Rep., 7, 8639, 10.1038/s41598-017-09379-8 · doi:10.1038/s41598-017-09379-8
- Bellotti, 2019, J. Mater. Chem. B, 7, 1276, 10.1039/C8TB02976H · DOI
- Galgatte, 2014, Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation, Drug Deliv., 21, 62, 10.3109/10717544.2013.849778 · DOI · Paper page
- Ammar, 2018, Local delivery of mometasone furoate from an eluting endotracheal tube, J. Control. Release, 272, 54, 10.1016/j.jconrel.2018.01.005 · DOI
- Cho, 2018, Sinus microanatomy and microbiota in a rabbit model of rhinosinusitis, Front. Cell. Infect. Microbiol., 7, 540, 10.3389/fcimb.2017.00540 · DOI
- Bar-Ilan, 1986, The pattern of distribution of intraocular pressure in the albino rabbit, Graefes Arch. Clin. Exp. Ophthalmol., 224, 469, 10.1007/BF02173366 · doi:10.1007/bf02173366
- Sastre, 2012, Local and systemic safety of intranasal corticosteroids, J Investig Allergol Clin Immunol, 22, 1
- Keck, 2000, Temperature profile in the nasal cavity, Laryngoscope, 110, 651, 10.1097/00005537-200004000-00021 · DOI · Paper page
- Alava, 2012, Mometasone furoate gel: a novel in-office treatment of recalcitrant postoperative chronic rhinosinusitis, J. Otolaryngol. Head Neck Surg., 41, 183
- Altuntas, 2017, Formulation and evaluation of thermoreversible in situ nasal gels containing mometasone furoate for allergic rhinitis, AAPS PharmSciTech, 10.1208/s12249-017-0747-8 · doi:10.1208/s12249-017-0747-8
- Altuntaş, 2018, Effects of a thermosensitive in situ gel containing mometasone furoate on a rat allergic rhinitis model, Am. J. Rhinol. Allergy., 32, 132, 10.1177/1945892418764951 · doi:10.1177/1945892418764951
- Aksoy, 2017, Effect of a combination of mometasone furoate, levofloxacin, and retinyl palmitate with an in situ gel-forming nasal delivery system on nasal mucosa damage repair in an experimental rabbit model, Biomed. Pharmacother., 96, 603, 10.1016/j.biopha.2017.10.023 · DOI
- Pandey, 2017, Formulation, functional evaluation and ex vivo performance of thermoresponsive soluble gels - a platform for therapeutic delivery to mucosal sinus tissue, Eur. J. Pharm. Sci., 96, 499, 10.1016/j.ejps.2016.10.017 · DOI
- Rothstein, 2012, A retrospective mathematical analysis of controlled release design and experimentation, Mol. Pharm., 9, 3003, 10.1021/mp300388w · DOI
- Far, 2020, Developing biodegradable nanoparticles loaded with mometasone furoate for potential nasal drug delivery, ACS Omega., 5, 7432, 10.1021/acsomega.0c00111 · doi:10.1021/acsomega.0c00111
- Han, 2012, Effect of steroid-releasing sinus implants on postoperative medical and surgical interventions: an efficacy meta-analysis, Int. Forum Allergy Rhinol., 2, 271, 10.1002/alr.21044 · DOI
- Kern, 2018, A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps, Int. Forum Allergy Rhinol., 8, 471, 10.1002/alr.22084 · DOI
- Dkhar, 2018, Intranasal drug delivery devices and interventions associated with post-operative endoscopic sinus surgery, Pharm. Dev. Technol., 23, 282, 10.1080/10837450.2017.1389956 · DOI
- Rothstein, 2011, A “tool box” for rational design of degradable controlled release formulations, J. Mater. Chem., 21, 29, 10.1039/C0JM01668C · DOI
- Kumar, 2016, Airflow in the human nasal passage and sinuses of chronic rhinosinusitis subjects, PLoS One, 11, 1, 10.1371/journal.pone.0156379 · DOI
- Xi, 2016, Anatomical details of the rabbit nasal passages and their implications in breathing, air conditioning, and olfaction, Anat. Rec., 299, 853, 10.1002/ar.23367 · doi:10.1002/ar.23367
- Ball, 2015, How reliable are sino-nasal cell lines for studying the pathophysiology of chronic rhinosinusitis?, Ann. Otol. Rhinol. Laryngol., 124, 437, 10.1177/0003489414565003 · doi:10.1177/0003489414565003
- Lee, 2017, Sinonasal delivery of resveratrol via Mucoadhesive nanostructured microparticles in a nasal polyp mouse model, Sci. Rep., 7, 40249, 10.1038/srep40249 · DOI
- Al-Sayed, 2017, Models for the study of nasal and sinus physiology in health and disease: a review of the literature, Laryngoscope Investig. Otolaryngol., 2, 398, 10.1002/lio2.117 · DOI
- Şimşek, 2016, The effect of long-term use of intranasal steroids on intraocular pressure, Clin. Ophthalmol., 10, 1079, 10.2147/OPTH.S106392 · DOI
- Bross-Soriano, 2004, Effects of three nasal topical steroids in the intraocular pressure compartment, Otolaryngol. Head Neck Surg., 130, 187, 10.1016/j.otohns.2003.09.020 · doi:10.1016/j.otohns.2003.09.020
- Zinreich, 2004, Imaging for staging of rhinosinusitis, Ann. Otol. Rhinol. Laryngol., 113, 19, 10.1177/00034894041130S506 · DOI
- Ozcan, 2011, Comparison of histopathological and CT findings in experimental rabbit sinusitis, Indian J. Otolaryngol. Head Neck Surg., 63, 56, 10.1007/s12070-011-0120-2 · doi:10.1007/s12070-011-0120-2
- Kerschner, 2000, Computed tomography vs. magnetic resonance imaging of acute bacterial sinusitis: a rabbit model, Am. J. Otolaryngol., 21, 298, 10.1053/ajot.2000.9874 · doi:10.1053/ajot.2000.9874
- Hounsfield, 1980, Computed medical imaging, Science (80), 210, 22, 10.1126/science.6997993 · DOI · Paper page
- Cho, 2006, CT analysis and histopathology of bone remodeling in patients with chronic rhinosinusitis, Otolaryngol. Head Neck Surg., 135, 404, 10.1016/j.otohns.2006.04.005 · DOI
- Szefler, 2001, Pharmacokinetics of intranasal corticosteroids, J. Allergy Clin. Immunol., 108, S26, 10.1067/mai.2001.115563 · DOI
- Teng, 2003, Degradation kinetics of mometasone furoate in aqueous systems, Int. J. Pharm., 259, 129, 10.1016/S0378-5173(03)00226-6 · DOI
- Doty, 2017, Mechanisms of in vivo release of triamcinolone acetonide from PLGA microspheres, J. Control. Release, 256, 19, 10.1016/j.jconrel.2017.03.031 · DOI
Cited by
Yathavan, B., Chhibber, T., Steinhauff, D., Pulsipher, A., Alt, J. A., Ghandehari, H., & Jafari, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102426 · Cited by 20
Metadata
- Authors
- Schilling, A. L., Kulahci, Y., Moore, J., Wang, E. W., Lee, S. E., & Little, S. R.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 330
- Pages
- 889-897
- ISSN
- 0168-3659
- Cited by
- 40
- References
- 2
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- Eye and Ear Foundation of Pittsburgh
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.